Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F1 mice

Journal of Immunology

Volumn 184, Issue 9, 2010, Pages 4789-4800

  Haas, Karen M ^a   Watanabe, Rei ^b   Matsushita, Takashi ^a   Nakashima, Hiroko ^b   Ishiura, Nobuko ^b   Okochi, Hitoshi ^b   Fujimoto, Manabu ^a,c   Tedder, Thomas F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; MB 2011; MB 2211; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; MONOCLONAL ANTIBODY CD22; PRISTANE; UNCLASSIFIED DRUG; AUTOANTIBODY; CD20 ANTIGEN; CD22 ANTIGEN; CD22 PROTEIN, MOUSE; TERPENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELL EXPANSION; CELL MATURATION; CELL TYPE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG EFFICACY; FEMALE; IMMUNOPATHOGENESIS; LOW DRUG DOSE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SINGLE DRUG DOSE; STRAIN DIFFERENCE; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; COMPARATIVE STUDY; CROSS BREEDING; DISEASE MODEL; IMMUNOLOGY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MORTALITY; NEW ZEALAND BLACK MOUSE; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIGENS, CD22; AUTOANTIBODIES; B-LYMPHOCYTE SUBSETS; CROSSES, GENETIC; DISEASE MODELS, ANIMAL; FEMALE; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED NZB; SURVIVAL RATE; TERPENES;

EID: 77954473511     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902391     Document Type: Article

References (68)

1. Lipsky, P. E. 2001. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat. Immunol. 2: 764-766.
2. Grammer, A. C., R. Slota, R. Fischer, H. Gur, H. Girschick, C. Yarboro, G. G. Illei, and P. E. Lipsky. 2003. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J. Clin. Invest. 112: 1506-1520.
3. Hahn, B. H., and R. R. Singh. 2006. Animal models of systemic lupus erythematosus. In Dubois' lupus erythematosus, 7th Ed., D. J. Wallace, B. Hahn, and E. L. Dubois, eds. Lippincott Williams & Wilkins, Philadelphia, PA, p. 299-355.
4. Wither, J. E., V. Roy, and L. A. Brennan. 2000. Activated B cells express increased levels of costimulatory molecules in young autoimmune NZB and (NZB x NZW)F(1) mice. Clin. Immunol. 94: 51-63.
5. Schuster, H., T. Martin, L. Marcellin, J. C. Garaud, J. L. Pasquali, and A. S. Korganow. 2002. Expansion of marginal zone B cells is not sufficient for the development of renal disease in NZBxNZW F1 mice. Lupus 11: 277-286. (Pubitemid 34627429)
6. Atencio, S., H. Amano, S. Izui, and B. L. Kotzin. 2004. Separation of the New Zealand Black genetic contribution to lupus from New Zealand Black determined expansions of marginal zone B and B1a cells. J. Immunol. 172: 4159-4166. (Pubitemid 38375228)
7. Hayakawa, K., R. R. Hardy, D. R. Parks, and L. A. Herzenberg. 1983. The "Ly-1 B" cell subpopulation in normal immunodefective, and autoimmune mice. J. Exp. Med. 157: 202-218.
8. Wofsy, D., and N. Y. Chiang. 1987. Proliferation of Ly-1 B cells in autoimmune NZB and (NZB x NZW)F1 mice. Eur. J. Immunol. 17: 809-814.
9. Xu, Z., E. J. Butfiloski, E. S. Sobel, and L. Morel. 2004. Mechanisms of peritoneal B-1a cells accumulation induced by murine lupus susceptibility locus Sle2. J. Immunol. 173: 6050-6058. (Pubitemid 39487760)
10. Izui, S., P. J. McConahey, and F. J. Dixon. 1978. Increased spontaneous polyclonal activation of B lymphocytes in mice with spontaneous autoimmune disease. J. Immunol. 121: 2213-2219. (Pubitemid 9075185)
11. Vyse, T. J., R. K. Halterman, S. J. Rozzo, S. Izui, and B. L. Kotzin. 1999. Control of separate pathogenic autoantibody responses marks MHC gene contributions to murine lupus. Proc. Natl. Acad. Sci. USA 96: 8098-8103.
12. Chan, O. T., M. P. Madaio, and M. J. Shlomchik. 1999. The central and multiple roles of B cells in lupus pathogenesis. Immunol. Rev. 169: 107-121.
13. Yanaba, K., J. D. Bouaziz, T. Matsushita, C. M. Magro, E. W. St Clair, and T. F. Tedder. 2008. B-lymphocyte contributions to human autoimmune disease. Immunol. Rev. 223: 284-299.
14. Chan, O., and M. J. Shlomchik. 1998. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J. Immunol. 160: 51-59. (Pubitemid 28116714)
15. O'Neill, S. K., M. J. Shlomchik, T. T. Glant, Y. Cao, P. D. Doodes, and A. Finnegan. 2005. Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J. Immunol. 174: 3781-3788.
16. + T cell activation in mice. Proc. Natl. Acad. Sci. USA 104: 20878-20883.
17. Ronchese, F., and B. Hausmann. 1993. B lymphocytes in vivo fail to prime naive T cells but can stimulate antigen-experienced T lymphocytes. J. Exp. Med. 177: 679-690.
18. Chan, O. T., L. G. Hannum, A. M. Haberman, M. P. Madaio, and M. J. Shlomchik. 1999. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 189: 1639-1648.
19. Shlomchik, M. J., M. P. Madaio, D. Ni, M. Trounstein, and D. Huszar. 1994. The role of B cells in lpr/lpr-induced autoimmunity. J. Exp. Med. 180: 1295-1306.
20. João, C., B. M. Ogle, C. Gay-Rabinstein, J. L. Platt, and M. Cascalho. 2004. B cell-dependent TCR diversification. J. Immunol. 172: 4709-4716.
21. AbuAttieh, M., M. Rebrovich, P. J. Wettstein, Z. Vuk-Pavlovic, A. H. Limper, J. L. Platt, and M. Cascalho. 2007. Fitness of cell-mediated immunity independent of repertoire diversity. J. Immunol. 178: 2950-2960. (Pubitemid 46333174)
22. Moulin, V., F. Andris, K. Thielemans, C. Maliszewski, J. Urbain, and M. Moser. 2000. B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J. Exp. Med. 192: 475-482.
23. Ngo, V. N., R. J. Cornall, and J. G. Cyster. 2001. Splenic T zone development is B cell dependent. J. Exp. Med. 194: 1649-1660.
24. Golovkina, T. V., M. Shlomchik, L. Hannum, and A. Chervonsky. 1999. Organogenic role of B lymphocytes in mucosal immunity. Science 286: 1965-1968. (Pubitemid 129515907)
25. Crowley, M. T., C. R. Reilly, and D. Lo. 1999. Influence of lymphocytes on the presence and organization of dendritic cell subsets in the spleen. J. Immunol. 163: 4894-4900.
26. + phenotype controls T cell-dependent inflammatory responses. Immunity 28: 639-650.
27. Matsushita, T., K. Yanaba, J.-D. Bouaziz, M. Fujimoto, and T. F. Tedder. 2008. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118: 3420-3430.
28. Bouaziz, J.-D., K. Yanaba, and T. F. Tedder. 2008. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol. Rev. 224: 201-214.
29. Anolik, J. H., J. Barnard, A. Cappione, A. E. Pugh-Bernard, R. E. Felgar, R. J. Looney, and I. Sanz. 2004. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 50: 3580-3590.
30. Looney, R. J., J. H. Anolik, D. Campbell, R. E. Felgar, F. Young, L. J. Arend, J. A. Sloand, J. Rosenblatt, and I. Sanz. 2004. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50: 2580-2589.
31. Gottenberg, J. E., L. Guillevin, O. Lambotte, B. Combe, Y. Allanore, A. Cantagrel, C. Larroche, M. Soubrier, L. Bouillet, M. Dougados, et al; Club Rheumatismes et Inflammation (CRI). 2005. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum. Dis. 64: 913-920.
32. Ding, C., S. Foote, and G. Jones. 2008. B-cell-targeted therapy for systemic lupus erythematosus: an update. BioDrugs 22: 239-249. (Pubitemid 351969831)
33. Karim, M. Y., C. N. Pisoni, and M. A. Khamashta. 2009. Update on immunotherapy for systemic lupus erythematosus - what's hot and what's not! Rheumatology (Oxford) 48: 332-341.
34. Ahuja, A., J. Shupe, R. Dunn, M. Kashgarian, M. R. Kehry, and M. J. Shlomchik. 2007. Depletion of B cells in murine lupus: efficacy and resistance. J. Immunol. 179: 3351-3361.
35. St Clair, E. W., and T. F. Tedder. 2006. New prospects for autoimmune disease therapy: B cells on deathwatch. Arthritis Rheum. 54: 1-9.
36. Haas, K. M., S. Sen, I. G. Sanford, A. S. Miller, J. C. Poe, and T. F. Tedder. 2006. CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo. J. Immunol. 177: 3063-3073.
37. Uchida, J., Y. Hamaguchi, J. A. Oliver, J. V. Ravetch, J. C. Poe, K. M. Haas, and T. F. Tedder. 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199: 1659-1669.
38. Uchida, J., Y. Lee, M. Hasegawa, Y. Liang, A. Bradney, J. A. Oliver, K. Bowen, D. A. Steeber, K. M. Haas, J. C. Poe, and T. F. Tedder. 2004. Mouse CD20 expression and function. Int. Immunol. 16: 119-129.
39. Hasegawa, M., Y. Hamaguchi, K. Yanaba, J.-D. Bouaziz, J. Uchida, M. Fujimoto, T. Matsushita, Y. Matsushita, M. Horikawa, K. Komura, et al. 2006. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am. J. Pathol. 169: 954-966.
40. Yanaba, K., Y. Hamaguchi, G. M. Venturi, D. A. Steeber, E. W. St Clair, and T. F. Tedder. 2007. B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J. Immunol. 179: 1369-1380.
41. Hu, C. Y., D. Rodriguez-Pinto, W. Du, A. Ahuja, O. Henegariu, F. S. Wong, M. J. Shlomchik, and L. Wen. 2007. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest. 117: 3857-3867.
42. Xiu, Y., C. P. Wong, J. D. Bouaziz, Y. Hamaguchi, Y. Wang, S. M. Pop, R. M. Tisch, and T. F. Tedder. 2008. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabeticmice despite isotype-specific differences in Fc γ R effector functions. J. Immunol. 180: 2863-2875.
43. Yu, S., R. Dunn, M. R. Kehry, and H. Braley-Mullen. 2008. B cell depletion inhibits spontaneous autoimmune thyroiditis in NOD. H-2h4 mice. J. Immunol. 180: 7706-7713.
44. + T cell reactivity. J. Immunol. 180: 4994-5003.
45. Hamaguchi, Y., J. Uchida, D. W. Cain, G. M. Venturi, J. C. Poe, K. M. Haas, and T. F. Tedder. 2005. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J. Immunol. 174: 4389-4399. (Pubitemid 40396022)
46. Poe, J. C., Y. Fujimoto, M. Hasegawa, K. M. Haas, A. S. Miller, I. G. Sanford, C. B. Bock, M. Fujimoto, and T. F. Tedder. 2004. CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms. Nat. Immunol. 5: 1078-1087.
47. Hamaguchi, Y., Y. Xiu, K. Komura, F. Nimmerjahn, and T. F. Tedder. 2006. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 203: 743-753.
48. Yanaba, K., J.-D. Bouaziz, T. Matsushita, T. Tsubata, and T. F. Tedder. 2009. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J. Immunol. 182: 7459-7472.
49. Martin, R. M., J. L. Brady, and A. M. Lew. 1998. The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J. Immunol. Methods 212: 187-192.
50. Schreier, P. H., A. L. Bothwell, B. Mueller-Hill, and D. Baltimore. 1981. Multiple differences between the nucleic acid sequences of the IgG2aa and IgG2ab alleles of the mouse. Proc. Natl. Acad. Sci. USA 78: 4495-4499.
51. Haas, K. M., M. Hasegawa, D. A. Steeber, J. C. Poe, M. D. Zabel, C. B. Bock, D. R. Karp, D. E. Briles, J. H. Weis, and T. F. Tedder. 2002. Complement receptors CD21/35 link innate and protective immunity during Streptococcus pneumoniae infection by regulating IgG3 antibody responses. Immunity 17: 713-723.
52. Yoshida, H., M. Satoh, K. M. Behney, C. G. Lee, H. B. Richards, V. M. Shaheen, J. Q. Yang, R. R. Singh, and W. H. Reeves. 2002. Effect of an exogenous trigger on the pathogenesis of lupus in (NZB x NZW)F1 mice. Arthritis Rheum. 46: 2235-2244.
53. Lee, P. Y., Y. Kumagai, Y. Li, O. Takeuchi, H. Yoshida, J. Weinstein, E. S. Kellner, D. Nacionales, T. Barker, K. Kelly-Scumpia, et al. 2008. TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J. Exp. Med. 205: 2995-3006.
54. DiLillo, D. J., Y. Hamaguchi, Y. Ueda, K. Yang, J. Uchida, K. M. Haas, G. Kelsoe, and T. F. Tedder. 2008. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J. Immunol. 180: 361-371.
55. Van Snick, J. L., V. Stassin, and B. de Lestré. 1983. Isotypic and allotypic specificity of mouse rheumatoid factors. J. Exp. Med. 157: 1006-1019.
56. Sugisaki, T., and S. Takase. 1991. Composition of immune deposits present in glomeruli of NZB/W F1 mice. Clin. Immunol. Immunopathol. 61: 296-308.
57. DiLillo, D. J., T. Matsushita, and T. F. Tedder. 2010. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann. N. Y. Acad. Sci. 1183: 38-57.
58. Fillatreau, S., C. H. Sweenie, M. J. McGeachy, D. Gray, and S. M. Anderton. 2002. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 3: 944-950.
59. Mauri, C., D. Gray, N. Mushtaq, and M. Londei. 2003. Prevention of arthritis by interleukin 10-producing B cells. J. Exp. Med. 197: 489-501.
60. Evans, J. G., K. A. Chavez-Rueda, A. Eddaoudi, A. Meyer-Bahlburg, D. J. Rawlings, M. R. Ehrenstein, and C. Mauri. 2007. Novel suppressive function of transitional 2 B cells in experimental arthritis. J. Immunol. 178: 7868-7878.
61. Watanabe, R., N. Ishiura, H. Nakashima, Y. Kuwano, H. Okochi, K. Tamaki, S. Sato, T. F. Tedder, and M. Fujimoto. 2010. Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J. Immunol. 184: 4801-4809.
62. Leandro, M. J., G. Cambridge, J. C. Edwards, M. R. Ehrenstein, and D. A. Isenberg. 2005. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 44: 1542-1545. (Pubitemid 41742472)
63. Smith, K. G., R. B. Jones, S. M. Burns, and D. R. Jayne. 2006. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum. 54: 2970-2982.
64. Cambridge, G., M. J. Leandro, M. Teodorescu, J. Manson, A. Rahman, D. A. Isenberg, and J. C. Edwards. 2006. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum. 54: 3612-3622. (Pubitemid 44737173)
65. Emi Aikawa, N., J. F. de Carvalho, C. Artur Almeida Silva, and E. Bonfá. 2009. Immunogenicity of anti-TNF-α agents in autoimmune aiseases. Clin. Rev. Allergy Immunol. doi:10.1007/s12016-009-8140-3.
66. Thurlings, R. M., O. Teng, K. Vos, D. M. Gerlag, L. Aarden, S. O. Stapel, J. M. van Laar, P. P. Tak, and G. J. Wolbink. 2010. Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 69: 409-412.
67. Schmidt, E., K. Hennig, C. Mengede, D. Zillikens, and A. Kromminga. 2009. Immunogenicity of rituximab in patients with severe pemphigus. Clin. Immunol. 132: 334-341.
68. Beers, S. A., C. H. Chan, S. James, R. R. French, K. E. Attfield, C. M. Brennan, A. Ahuja, M. J. Shlomchik, M. S. Cragg, and M. J. Glennie. 2008. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 112: 4170-4177.